FCGR3A and plasma cell myeloma: The CD38 antibody daratumumab demonstrated marked cytotoxicity against myeloma cells through ADCC, which relies on binding of NK cell CD16 (FcγRIIIA), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).